Comparison of Slow Efficiency Daily Dialysis (SLEDD) With Unfractionated Heparin Versus Citrasate in Critically Ill Patients.

• Status: Unknown status
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the feasibility, safety and efficacy of hemodialysis with unfractionated heparin compared to hemodialysis with Citrasate in Critically Ill Patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Antwerp
• Treatments: Calcium heparin; Heparin

Criteria

Inclusion Criteria:

• Need for hemodialysis in the ICU for at least one treatment

• No prior hemodialysis treatment in the ICU except continuous renal replacement therapy

Exclusion Criteria:

• Need for systemic anticoagulation with unfractionated or fractionated heparin, oral anticoagulants or intravenous anti-aggregants for other reasons

• Need for continued thrombolysis therapy within the 6 hours before inclusion

• Need for continued treatment with activated protein C (drotrecogin alfa) within the 12 hours before inclusion

• Need for continued treatment with intravenous anti-aggregants (abciximab, eptifabide) within 12 hours before inclusion

• Liver failure (acute and acute-on-chronic)

• Confirmed or suspected Heparin Induced Thrombocytopenia (HIT)

• Heparin allergies

• Severe uncorrected hypocalcemia (ionized calcium < 0,8 mmol/l)

• Refusal of informed consent